MEA, Saudi Arabia, SEA Car-T Cell Therapy Market - Industry Trends and Forecast to 2031
MEA CAR-T cell therapy treatment market is expected to reach USD 105.69 million by 2031 growing with a CAGR of 28.5% in the forecast period of 2027 to 2031.
Market SegmentationMEA CAR-T Cell Therapy Treatment Market, By Product (Autologous CAR-T Cells and Allogeneic CAR-T Cells), Structure (First Generation CAR-T Cells, Second Generation Car-T Cells, Third Generation CAR-T Cells, and Fourth Generation CAR-T Cells), Targeted Antigens (Antigens On Solid Tumors, Antigens On Hematologic Malignancies, and Others), Brand (Yescarta, Kymriah, Tecartus, and Others), Therapeutic Application (Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Acute Lymphoblastic Leukaemia (ALL), Mantle Cell Lymphoma, Multiple Myeloma, Hematologic Malignancies, Lung Cancer, Chronic Lymphocytic Leukemia, Gastric Cancer, Pancreatic Cancer, Breast Cancer, and Others), End User (Hospitals, Specialty Clinics, and Others), Distribution Channel (Hospitals Pharmacy and Others), Country (Saudi Arabia, U.A.E., South Africa, Israel, Kuwait, Egypt, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031
Some of the major factors contributing to the growth of the MEA CAR-T cell therapy treatment market are:Overview of MEA, Saudi Arabia and SEA CAR-T Cell Therapy Treatment Market Dynamics:
• On the basis of product, the market is segmented into autologous CAR-T cells and allogeneic CAR-T cells
• On the basis of structure, the market is segmented into first generation CAR-T cells, second generation CAR-T cells, third generation CAR-T cells, and fourth generation CAR-T cells
• On the basis of targeted antigens, the market is segmented into antigens on solid tumors, antigens on hematologic malignancies and others
• On the basis of brand, the market is segmented into yescarta, kymriah, tecartus and others
• On the basis of therapeutic application, the market is segmented into diffuse large b-cell lymphoma, follicular lymphoma, Acute Lymphoblastic Leukaemia (ALL), mantle cell lymphoma, multiple myeloma, hematologic malignancies, lung cancer, chronic lymphocytic leukemia, gastric cancer, pancreatic cancer, breast cancer, and others
• On the basis of end user, the market is segmented into hospitals, specialty clinics and others
• On the basis of distribution channel, the market is segmented into hospitals pharmacy and others
Market PlayersSome of the market players operating in the MEA CAR-T cell therapy treatment market are listed below:
• Novartis AG,
• Gilead Sciences, Inc.,
• Bristol-Myers Squibb Company,
• Johnson & Johnson Services, Inc.
SEA CAR-T cell therapy treatment market is expected to reach USD 108.95 million by 2031, growing with a CAGR of 30.7% in the forecast period of 2024 to 2031.
Market SegmentationSEA CAR-T Cell Therapy Treatment Market, By Product (Autologous CAR-T Cells and Allogeneic CAR-T Cells), Structure (First Generation CAR-T Cells, Second Generation Car-T Cells, Third Generation CAR-T Cells, and Fourth Generation CAR-T Cells), Targeted Antigens (Antigens On Solid Tumors, Antigens On Hematologic Malignancies, and Others), Brand (Yescarta, Kymriah, Tecartus, and Others), Therapeutic Application (Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Acute Lymphoblastic Leukaemia (ALL), Mantle Cell Lymphoma, Multiple Myeloma, Hematologic Malignancies, Lung Cancer, Chronic Lymphocytic Leukemia, Gastric Cancer, Pancreatic Cancer, Breast Cancer, and Others), End User (Hospitals, Specialty Clinics, and Others), Distribution Channel (Hospitals Pharmacy and Others), Country (Singapore, Indonesia, Thailand, Malaysia, Philippines, and Vietnam)- Industry Trends and Forecast to 2031
Some of the major factors contributing to the growth of the MEA, Saudi Arabia and SEA CAR-T cell therapy treatment market are:Overview of SEA CAR-T Cell Therapy Treatment Market Dynamics:
Drivers
• Increasing prevalence of cancer and other target diseases
• Growing awareness and acceptance of car-t cell therapy
• Supportive government initiatives and funding for healthcare innovation
Restraints
• High cost of car-t cell therapy
• Regulatory hurdles result the delay in car t-cell therapy approval
Opportunities
• The extensive pipeline of car-t cell therapy
• The development of novel therapies and combination treatments
Challenges
• Potential risks and adverse effects of treatment
• Competition from alternative treatments and therapies
Market Players Some of the market players operating in the SEA CAR-T cell therapy treatment market are listed below:
• Novartis AG,
• Gilead Sciences, Inc.,
• Bristol-Myers Squibb Company,
• Johnson & Johnson Services, Inc.
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.